Advances in cancer research最新文献_第2页

Precision medicine approaches to CNS metastatic disease. 精准医学方法治疗中枢神经系统转移性疾病。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-14 DOI: 10.1016/bs.acr.2025.04.005

Toni Cao, Meaghan Roy-O'Reilly, Seema Nagpal

{"title":"Precision medicine approaches to CNS metastatic disease.","authors":"Toni Cao, Meaghan Roy-O'Reilly, Seema Nagpal","doi":"10.1016/bs.acr.2025.04.005","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.04.005","url":null,"abstract":"Brain metastases (BrM) and leptomeningeal metastases (LM) are increasingly common neurologic complications of cancer. The era of precision oncology has ushered in a deeper understanding of the molecular alterations that drive oncogenesis, subsequently informing and accelerating the drug development process. New systemic treatments, including oral tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs) as well as antibody-drug conjugates (ADCs), have substantial intracranial efficacy with meaningful clinical benefit for BrM patients. Our understanding of LM continues to evolve with the development of improved detection methods and an increasing number of brain penetrant therapies. Targeted therapeutics continue to transform the existing treatment landscape and add both choice and complexity to the clinician's calculus when managing patients with BrM and/or LM. Multidisciplinary discussion should ultimately guide all treatment decisions and explore both the benefits and toxicities of various therapy options. Systemic targeted therapies should be considered for patients with asymptomatic or minimally symptomatic small BrM and/or LM. Future studies investigating treatment timing and effective combinatorial strategies are urgently needed.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"57-114"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiation therapy for cerebral metastases: Non-stereotactic treatment options. 脑转移瘤的放射治疗：非立体定向治疗选择。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-21 DOI: 10.1016/bs.acr.2025.04.008

John G Roubil, Timothy J Harris

引用次数: 0

Stereotactic radiosurgery for brain metastases. 立体定向放射外科治疗脑转移瘤。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-04-24 DOI: 10.1016/bs.acr.2025.04.001

Stylianos Pikis, Maria Protopapa, Georgios Mantziaris, Mahmoud Osama, Jason Sheehan

{"title":"Stereotactic radiosurgery for brain metastases.","authors":"Stylianos Pikis, Maria Protopapa, Georgios Mantziaris, Mahmoud Osama, Jason Sheehan","doi":"10.1016/bs.acr.2025.04.001","DOIUrl":"https://doi.org/10.1016/bs.acr.2025.04.001","url":null,"abstract":"Brain metastases are the most common intracranial malignancies in adults, and, depending on primary tumor type, they may affect up to 50 % of cancer patients. Although advances in systemic and local therapies have led to improvements in patient overall survival and progression free survival, there remains substantial opportunities to improve patient outcomes. Stereotactic radiosurgery (SRS) delivers high doses of ionizing radiation with sub-millimeter accuracy to discrete intracranial tumors. It has emerged as the standard of care for patients with limited number of brain metastases, and it serves as a valuable adjuvant after resection. Moreover, SRS is typically seamlessly integrated into systemic therapy treatment regimens. Continued improvement in SRS technology and growing evidence have led to expansion of SRS indications and introduction of new SRS techniques. Frameless SRS technologies have allowed for treatment of larger lesions and even lesions adjacent to critical structures for which single session SRS would not be prudent. Neoadjuvant SRS has recently been proposed as an alternative to adjuvant SRS and appears to help reduce the risk of leptomeningeal dissemination. These novel SRS techniques require further evaluation through prospective clinical trials and registry based studies. In addition, the concurrent combination of systemic therapies with central nervous system (CNS) activity and SRS has yielded promising results with respect to local control and adverse radiation events rates. The concurrent delivery of SRS, precision medicine, and/or immunotherapy requires further refinements to fully optimize patient outcomes. In this review, we detail the current literature on established and forthcoming indications of SRS for brain metastases.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"165 ","pages":"115-143"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144304249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The history of LITT for the treatment of active brain metastasis and radiation necrosis. LITT治疗活动性脑转移和放射性坏死的历史。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-08 DOI: 10.1016/bs.acr.2025.04.002

Theresa Gammel, Shawn D'Souza, William Broaddus

引用次数: 0

Intraoperative imaging techniques to improve tumor detection in the surgical management of gliomas. 术中影像技术提高胶质瘤手术治疗中的肿瘤检测。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-05-23 DOI: 10.1016/bs.acr.2025.05.001

David Bailey, Brad E Zacharia

引用次数: 0

Radiotherapeutic approaches in the treatment of adult gliomas. 成人胶质瘤的放射治疗方法。

Advances in cancer research Pub Date : 2025-01-01 Epub Date: 2025-06-19 DOI: 10.1016/bs.acr.2025.05.007

John G Roubil, Timothy J Harris

引用次数: 0

Advancing cancer therapeutics: Integrating scalable 3D cancer models, extracellular vesicles, and omics for enhanced therapy efficacy. 推进癌症治疗：整合可扩展的三维癌症模型、细胞外囊泡和 omics，提高疗效。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-07-20 DOI: 10.1016/bs.acr.2024.07.001

Pedro P Gonçalves, Cláudia L da Silva, Nuno Bernardes

{"title":"Advancing cancer therapeutics: Integrating scalable 3D cancer models, extracellular vesicles, and omics for enhanced therapy efficacy.","authors":"Pedro P Gonçalves, Cláudia L da Silva, Nuno Bernardes","doi":"10.1016/bs.acr.2024.07.001","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.07.001","url":null,"abstract":"Cancer remains as one of the highest challenges to human health. However, anticancer drugs exhibit one of the highest attrition rates compared to other therapeutic interventions. In part, this can be attributed to a prevalent use of in vitro models with limited recapitulative potential of the in vivo settings. Three dimensional (3D) models, such as tumor spheroids and organoids, offer many research opportunities to address the urgent need in developing models capable to more accurately mimic cancer biology and drug resistance profiles. However, their wide adoption in high-throughput pre-clinical studies is dependent on scalable manufacturing to support large-scale therapeutic drug screenings and multi-omic approaches for their comprehensive cellular and molecular characterization. Extracellular vesicles (EVs), which have been emerging as promising drug delivery systems (DDS), stand to significantly benefit from such screenings conducted in realistic cancer models. Furthermore, the integration of these nanomedicines with 3D cancer models and omics profiling holds the potential to deepen our understanding of EV-mediated anticancer effects. In this chapter, we provide an overview of the existing 3D models used in cancer research, namely spheroids and organoids, the innovations in their scalable production and discuss how omics can facilitate the implementation of these models at different stages of drug testing. We also explore how EVs can advance drug delivery in cancer therapies and how the synergy between 3D cancer models and omics approaches can benefit in this process.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"163 ","pages":"137-185"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitochondrial metallopeptidase OMA1 in cancer. 癌症中的线粒体金属肽酶 OMA1

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-22 DOI: 10.1016/bs.acr.2024.05.001

Gunjan Purohit, Polash Ghosh, Oleh Khalimonchuk

引用次数: 0

Deciphering the genetic and epigenetic architecture of prostate cancer. 解密前列腺癌的基因和表观遗传结构。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-06-22 DOI: 10.1016/bs.acr.2024.06.001

Sheeraz Un Nazir, Juhi Mishra, Shailendra Kumar Maurya, Negin Ziamiavaghi, Sanika Bodas, Benjamin A Teply, Samikshan Dutta, Kaustubh Datta

{"title":"Deciphering the genetic and epigenetic architecture of prostate cancer.","authors":"Sheeraz Un Nazir, Juhi Mishra, Shailendra Kumar Maurya, Negin Ziamiavaghi, Sanika Bodas, Benjamin A Teply, Samikshan Dutta, Kaustubh Datta","doi":"10.1016/bs.acr.2024.06.001","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.06.001","url":null,"abstract":"Prostate cancer, one of the most frequently diagnosed cancers in men, leads to significant mortality worldwide. Its study is important due to the complexity and diversity in its progression, highlighting the urgent need for improved therapeutic strategies. This chapter probes into the genetic and epigenetic factors influencing prostate cancer progression, underscoring the importance of understanding the disease's molecular fundamentals for the development of targeted therapies. It specifically reviews the role of key genetic mutations in genes such as Androgen Receptor, TP53, SPOP, FOXA1 and PTEN which are crucial for the disease onset and a progression. Furthermore, it examines the impact of epigenetic modifications, including DNA methylation and histone modification, which contribute to the cancer's progression by affecting gene expression and cellular behavior. Further, in this chapter we delve into the underlying signaling mechanism, the advancements in targeting genetic and epigenetic alterations in prostate cancer. These findings have revealed promising targets for therapeutic advancements, aiming to understand and identify promising avenues for future therapies. This chapter improves our current understanding of prostate cancer genetic and epigenetic landscape, emphasizing the necessity of advancing our knowledge to refine and expand treatment options for prostate cancer patients.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"191-221"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Understanding the molecular regulators of neuroendocrine prostate cancer. 了解神经内分泌性前列腺癌的分子调控因子。

Advances in cancer research Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1016/bs.acr.2024.04.006

Sreyashi Bhattacharya, Avery Stillahn, Kaitlin Smith, Michael Muders, Kaustubh Datta, Samikshan Dutta

{"title":"Understanding the molecular regulators of neuroendocrine prostate cancer.","authors":"Sreyashi Bhattacharya, Avery Stillahn, Kaitlin Smith, Michael Muders, Kaustubh Datta, Samikshan Dutta","doi":"10.1016/bs.acr.2024.04.006","DOIUrl":"https://doi.org/10.1016/bs.acr.2024.04.006","url":null,"abstract":"Worldwide, prostate cancer (PCa) remains a leading cause of death in men. Histologically, the majority of PCa cases are classified as adenocarcinomas, which are mainly composed of androgen receptor-positive luminal cells. PCa is initially driven by the androgen receptor axis, where androgen-mediated activation of the receptor is one of the primary culprits for disease progression. Therefore, in advanced stage PCa, patients are generally treated with androgen deprivation therapies alone or in combination with androgen receptor pathway inhibitors. However, after an initial decrease, the cancer recurs for majority patients. At this stage, cancer is known as castration-resistant prostate cancer (CRPC). Majority of CRPC tumors still depend on androgen receptor axis for its progression to metastasis. However, in around 20-30% of cases, CRPC progresses via an androgen receptor-independent pathway and is often presented as neuroendocrine cancer (NE). This NE phenotype is highly aggressive with poor overall survival as compared to CRPC adenocarcinoma. NE cancers are resistant to standard taxane chemotherapies, which are often used to treat metastatic disease. Pathologically and morphologically, NE cancers are highly diverse and often co-exist with adenocarcinoma. Due to the lack of proper biomarkers, it is often difficult to make an early diagnosis of this lethal disease. Moreover, increased tumor heterogeneity and admixtures of adeno and NE subtypes in the same tumor make early detection of NE tumors very difficult. With the advancement of our knowledge and sequencing technology, we are now able to better understand the molecular mediators of this transformation pathway. This current study will give an update on how various molecular regulators are involved in these lineage transformation processes and what challenges we are still facing to detect and treat this cancer.","PeriodicalId":94294,"journal":{"name":"Advances in cancer research","volume":"161 ","pages":"403-429"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0